{"success":true,"data":{"pressRelease":{"id":"163578","rtpr_id":"nGNX4zQmgm-20261007","ticker":"PROF","exchange":"NASDAQ","all_tickers":["PROF","PRN"],"title":"Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue","author":"Globe Newswire","published_at":"2026-10-07T20:15:00.214Z","article_body":"TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp.\n(https://www.globenewswire.com/Tracker?data=Le093yoohDAFfqfLTizaQkQZ6DxZKQkiWj08haBs8u_LtuLqZ4Ijq2hWKibQvjXIGHHx-Ms7ItVMNa7IWdkaQqs0IvsIIJ7J9pI4mSzweSU=)\n(NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a\ncommercial-stage medical device company that develops and markets innovative\ninterventional MRI (iMRI) procedures, today announced preliminary unaudited\nrevenues for the third quarter ended September 30, 2026. Unless specified\notherwise, all amounts in this press release are expressed in U.S. dollars.\n\nBased on these preliminary results, the Company expects to report\nrecord-breaking quarterly revenue that is above current Wall Street\nexpectations.\n\nPreliminary Financial Highlights:\n* Total Revenue: Expected to be in the range of $9.8 million to $10.0 million.\n\n\n* Year-over-Year Growth: Expected to increase approximately 85% to 89%\ncompared with $5.3 million in the third quarter of 2025.\n\n\n* Sequential Quarter-over-Quarter Growth: Expected to increase approximately\n292% to 300% compared with $2.5 million in the second quarter of 2026.\n\n\n* Versus Consensus: Expected revenue is approximately 45% to 47% above the\nBloomberg mean analyst consensus of $6.78 million.(1)\n\n\n* Gross Margin: Q3-2026 gross margin is again expected to exceed 70%,\nreflecting continued progress in the Company’s commercial operations and\nscale.\n“The significant increase in revenue we expect to report this quarter\nrepresents a historic milestone for Profound, reflecting the strong commercial\nmomentum building behind our technology,” said Arun Menawat, Profound’s\nCEO and Chairman. “The expected year-over-year and sequential growth in the\nthird quarter reflects increased commercial activity across our installed base\nand new customer accounts.”\n\nDr. Menawat continued, “With preliminary revenue of approximately $9.8\nmillion to $10.0 million and gross margin expected to exceed 70%, we believe\nthe third quarter represents an important step in the continued expansion of\nour commercial business. We remain focused on supporting customer adoption,\nincreasing utilization of our installed base, and building a profitable growth\ncompany over the long-term.”\n\nThese figures are preliminary and unaudited, and actual revenues may differ.\nIn addition, consensus estimates are based on the work of third-party\nanalysts, and the Company does not endorse, adopt, or control them. Profound\nintends to report full third quarter 2026 financial results after market close\non Thursday, November 5th and will host a conference call at 4:30 p.m. ET to\nreview the financial results and discuss business developments in the period.\n\nThird Quarter 2026 Results Conference Call Details:\n\nDate: Thursday, November 5, 2026\n\nTime: 4:30 p.m. ET\n\nLive Call Registration:\nhttps://register-conf.media-server.com/register/BI38c9375e5dd147bc971da6a4bb029d8c\n\nThe call will also be broadcast live and archived on the Company's website in\nthe Investors section here.\n\nSource\n\n(1) As compared to the Bloomberg consensus estimate compiled as of October 7,\n2026 at 9:02 a.m. ET.\n\nAbout Profound Medical Corp.\n\nProfound is a commercial-stage medical device company and an innovator in\ninterventional MRI (iMRI) procedures. The company’s flagship platform,\nTULSA-PRO(®)\n(https://www.globenewswire.com/Tracker?data=6LbJOXMmCkyHBXDBYpS-HaNjQO6grvPR1IOoO1Bi1N0ErrlS5Y0EzksTmdMGhOECdRScvEOIq-VZFjwaeikcy7II8zZAATjEehMec0NiinU=),\nenables MRI-guided, incision-free prostate ablation. Physicians use the TULSA\nProcedure™\n(https://www.globenewswire.com/Tracker?data=6LbJOXMmCkyHBXDBYpS-HUwAUj5-HuKeFq6Xe8eGqijaGKbAS_aOhOePJPJ31WzMO4ZVozrUHZwsrNYoFNkZpCg-FGC2TU5Y4L6TxAUa9sgA0ZUMr-qp9A-1FkvftVcEjkl_PPt90aWf93nDSJ572w==)\nto see, ablate, and confirm therapy in real time, supporting personalized\ntreatment strategies across the continuum of prostate care—from whole-gland\nto subtotal, hemi, multifocal, and focal treatment. This approach enables\nindividualized care using prostate tissue ablation, while minimizing the\npotential of the side effects that are typically associated with surgery or\nradiation, such as urinary incontinence and/or erectile dysfunction.\n\nProfound also commercializes Sonalleve(®)\n(https://www.globenewswire.com/Tracker?data=iO2yMToUgfkLsiFYkzx6UQST8xvjUA2U4DfvWfEVDNL_v6qHXoI14tilFxiY6yJyXDGJb0lGcHsR_pRbtuzse7v-WsUXLqkC7g0NA5hC-ac=),\nan MRI-guided therapy that provides a non-surgical treatment option for pain\npalliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as\nfor common gynecologic conditions including uterine fibroids and adenomyosis.\nSonalleve delivers targeted therapy with no incisions, no blood loss during\nthe procedure, no overnight hospital stay, and faster recovery — and, in\ngynecologic applications, enables uterine-sparing treatment that may help\npreserve fertility. Profound is also exploring additional clinical\napplications for Sonalleve, including non-invasive ablation of abdominal\ncancers and hyperthermia-based cancer therapies.\n\nProfound Medical’s technologies are approved across major global markets.\nTULSA-PRO is cleared by the FDA in the United States for transurethral\nultrasound ablation (TULSA) of prostate tissue. In addition, TULSA-PRO is\ncleared for use in various jurisdictions including Europe, Canada, Saudi\nArabia, India, Australia/New Zealand, and the UAE. Sonalleve is approved by\nthe FDA as HDE in the United States for the treatment of osteoid osteomas in\nthe extremities. Sonalleve is also cleared or approved in the Europe, Canada,\nChina, and Saudi Arabia.\n\nThrough real-time MRI guidance and data-driven innovation, Profound is\nadvancing the future of MRI-guided therapy — expanding access to precise,\npersonalized, and incision-free treatment options worldwide.\n\nForward-Looking Statements\n\nThis release includes forward-looking statements regarding Profound and its\nbusiness which may include, but is not limited to, the expectations regarding\nthe efficacy of Profound’s technologies for disease conditions requiring\nMR-Guided ablation procedures for prostate, uterine fibroids, adenomyosis,\npalliative pain treatment, desmoid tumors, and osteoid osteoma; Profound’s\npreliminary unaudited third quarter 2026 revenues and gross margin;\nexpectations for future revenues/financial results; and the success of\nProfound’s commercialization strategy and activities for TULSA-PRO(®) and\nSonalleve(®). Often, but not always, forward-looking statements can be\nidentified by the use of words such as \"plans\", \"is expected\", \"expects\",\n\"scheduled\", \"intends\", \"contemplates\", \"anticipates\", \"believes\", \"proposes\"\nor variations (including negative variations) of such words and phrases, or\nstate that certain actions, events or results \"may\", \"could\", \"would\", \"might\"\nor \"will\" be taken, occur or be achieved. Such statements are based on the\ncurrent expectations of the management of Profound. The forward-looking events\nand circumstances discussed in this release, may not occur by certain\nspecified dates or at all and could differ materially as a result of known and\nunknown risk factors and uncertainties affecting the Company, including risks\nregarding the medical device industry, regulatory approvals, reimbursement,\neconomic factors, the equity markets generally and risks associated with\ngrowth and competition. Although Profound has attempted to identify important\nfactors that could cause actual actions, events or results to differ\nmaterially from those described in forward-looking statements, there may be\nother factors that cause actions, events or results to differ from those\nanticipated, estimated or intended. No forward-looking statement can be\nguaranteed. Other factors and risks that may cause actual results to differ\nmaterially from those set out in the forward-looking statements are described\nin Profound's Annual Report on Form 10-K and other filings made with U.S. and\nCanadian securities regulators, available at www.sedarplus.com and\nwww.sec.gov. Except as required by applicable securities laws, forward-looking\nstatements speak only as of the date on which they are made and Profound\nundertakes no obligation to publicly update or revise any forward-looking\nstatement, whether as a result of new information, future events, or\notherwise, other than as required by law.\n\nFinancial Outlook\n\nThis press release contains a financial outlook within the meaning of\napplicable securities laws. The financial outlook has been prepared by\nmanagement of the Company to provide an outlook for the Company’s forecasted\nrevenue for the three months ended September 30, 2026, and may not be\nappropriate for any other purpose. The financial outlook has been prepared\nbased on a number of assumptions, including the assumptions discussed under\nthe heading “Forward-Looking Statements” herein. The actual results of the\nCompany’s operations for any period may vary from the amounts set forth in\nthese projections, and such variations may be material. The Company and its\nmanagement believe that the financial outlook has been prepared on a\nreasonable basis. However, because this information is highly subjective and\nsubject to numerous risks, including the risks discussed under the heading\n“Forward-Looking Statements” herein, it should not be relied on as\nnecessarily indicative of future results.\n\nFor further information, please contact:\n\nStephen Kilmer\nInvestor Relations\nskilmer@profoundmedical.com\nT: 647.872.4849\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/94d9e057-9de3-430c-9a19-b41ff3e06a1e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4zQmgm-20261007","title":"Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue","author":"Globe Newswire","ticker":"PROF","created":"2026-10-07T20:15:00.214Z","tickers":["PROF","PRN"],"exchange":"NASDAQ","article_body":"TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp.\n(https://www.globenewswire.com/Tracker?data=Le093yoohDAFfqfLTizaQkQZ6DxZKQkiWj08haBs8u_LtuLqZ4Ijq2hWKibQvjXIGHHx-Ms7ItVMNa7IWdkaQqs0IvsIIJ7J9pI4mSzweSU=)\n(NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a\ncommercial-stage medical device company that develops and markets innovative\ninterventional MRI (iMRI) procedures, today announced preliminary unaudited\nrevenues for the third quarter ended September 30, 2026. Unless specified\notherwise, all amounts in this press release are expressed in U.S. dollars.\n\nBased on these preliminary results, the Company expects to report\nrecord-breaking quarterly revenue that is above current Wall Street\nexpectations.\n\nPreliminary Financial Highlights:\n* Total Revenue: Expected to be in the range of $9.8 million to $10.0 million.\n\n\n* Year-over-Year Growth: Expected to increase approximately 85% to 89%\ncompared with $5.3 million in the third quarter of 2025.\n\n\n* Sequential Quarter-over-Quarter Growth: Expected to increase approximately\n292% to 300% compared with $2.5 million in the second quarter of 2026.\n\n\n* Versus Consensus: Expected revenue is approximately 45% to 47% above the\nBloomberg mean analyst consensus of $6.78 million.(1)\n\n\n* Gross Margin: Q3-2026 gross margin is again expected to exceed 70%,\nreflecting continued progress in the Company’s commercial operations and\nscale.\n“The significant increase in revenue we expect to report this quarter\nrepresents a historic milestone for Profound, reflecting the strong commercial\nmomentum building behind our technology,” said Arun Menawat, Profound’s\nCEO and Chairman. “The expected year-over-year and sequential growth in the\nthird quarter reflects increased commercial activity across our installed base\nand new customer accounts.”\n\nDr. Menawat continued, “With preliminary revenue of approximately $9.8\nmillion to $10.0 million and gross margin expected to exceed 70%, we believe\nthe third quarter represents an important step in the continued expansion of\nour commercial business. We remain focused on supporting customer adoption,\nincreasing utilization of our installed base, and building a profitable growth\ncompany over the long-term.”\n\nThese figures are preliminary and unaudited, and actual revenues may differ.\nIn addition, consensus estimates are based on the work of third-party\nanalysts, and the Company does not endorse, adopt, or control them. Profound\nintends to report full third quarter 2026 financial results after market close\non Thursday, November 5th and will host a conference call at 4:30 p.m. ET to\nreview the financial results and discuss business developments in the period.\n\nThird Quarter 2026 Results Conference Call Details:\n\nDate: Thursday, November 5, 2026\n\nTime: 4:30 p.m. ET\n\nLive Call Registration:\nhttps://register-conf.media-server.com/register/BI38c9375e5dd147bc971da6a4bb029d8c\n\nThe call will also be broadcast live and archived on the Company's website in\nthe Investors section here.\n\nSource\n\n(1) As compared to the Bloomberg consensus estimate compiled as of October 7,\n2026 at 9:02 a.m. ET.\n\nAbout Profound Medical Corp.\n\nProfound is a commercial-stage medical device company and an innovator in\ninterventional MRI (iMRI) procedures. The company’s flagship platform,\nTULSA-PRO(®)\n(https://www.globenewswire.com/Tracker?data=6LbJOXMmCkyHBXDBYpS-HaNjQO6grvPR1IOoO1Bi1N0ErrlS5Y0EzksTmdMGhOECdRScvEOIq-VZFjwaeikcy7II8zZAATjEehMec0NiinU=),\nenables MRI-guided, incision-free prostate ablation. Physicians use the TULSA\nProcedure™\n(https://www.globenewswire.com/Tracker?data=6LbJOXMmCkyHBXDBYpS-HUwAUj5-HuKeFq6Xe8eGqijaGKbAS_aOhOePJPJ31WzMO4ZVozrUHZwsrNYoFNkZpCg-FGC2TU5Y4L6TxAUa9sgA0ZUMr-qp9A-1FkvftVcEjkl_PPt90aWf93nDSJ572w==)\nto see, ablate, and confirm therapy in real time, supporting personalized\ntreatment strategies across the continuum of prostate care—from whole-gland\nto subtotal, hemi, multifocal, and focal treatment. This approach enables\nindividualized care using prostate tissue ablation, while minimizing the\npotential of the side effects that are typically associated with surgery or\nradiation, such as urinary incontinence and/or erectile dysfunction.\n\nProfound also commercializes Sonalleve(®)\n(https://www.globenewswire.com/Tracker?data=iO2yMToUgfkLsiFYkzx6UQST8xvjUA2U4DfvWfEVDNL_v6qHXoI14tilFxiY6yJyXDGJb0lGcHsR_pRbtuzse7v-WsUXLqkC7g0NA5hC-ac=),\nan MRI-guided therapy that provides a non-surgical treatment option for pain\npalliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as\nfor common gynecologic conditions including uterine fibroids and adenomyosis.\nSonalleve delivers targeted therapy with no incisions, no blood loss during\nthe procedure, no overnight hospital stay, and faster recovery — and, in\ngynecologic applications, enables uterine-sparing treatment that may help\npreserve fertility. Profound is also exploring additional clinical\napplications for Sonalleve, including non-invasive ablation of abdominal\ncancers and hyperthermia-based cancer therapies.\n\nProfound Medical’s technologies are approved across major global markets.\nTULSA-PRO is cleared by the FDA in the United States for transurethral\nultrasound ablation (TULSA) of prostate tissue. In addition, TULSA-PRO is\ncleared for use in various jurisdictions including Europe, Canada, Saudi\nArabia, India, Australia/New Zealand, and the UAE. Sonalleve is approved by\nthe FDA as HDE in the United States for the treatment of osteoid osteomas in\nthe extremities. Sonalleve is also cleared or approved in the Europe, Canada,\nChina, and Saudi Arabia.\n\nThrough real-time MRI guidance and data-driven innovation, Profound is\nadvancing the future of MRI-guided therapy — expanding access to precise,\npersonalized, and incision-free treatment options worldwide.\n\nForward-Looking Statements\n\nThis release includes forward-looking statements regarding Profound and its\nbusiness which may include, but is not limited to, the expectations regarding\nthe efficacy of Profound’s technologies for disease conditions requiring\nMR-Guided ablation procedures for prostate, uterine fibroids, adenomyosis,\npalliative pain treatment, desmoid tumors, and osteoid osteoma; Profound’s\npreliminary unaudited third quarter 2026 revenues and gross margin;\nexpectations for future revenues/financial results; and the success of\nProfound’s commercialization strategy and activities for TULSA-PRO(®) and\nSonalleve(®). Often, but not always, forward-looking statements can be\nidentified by the use of words such as \"plans\", \"is expected\", \"expects\",\n\"scheduled\", \"intends\", \"contemplates\", \"anticipates\", \"believes\", \"proposes\"\nor variations (including negative variations) of such words and phrases, or\nstate that certain actions, events or results \"may\", \"could\", \"would\", \"might\"\nor \"will\" be taken, occur or be achieved. Such statements are based on the\ncurrent expectations of the management of Profound. The forward-looking events\nand circumstances discussed in this release, may not occur by certain\nspecified dates or at all and could differ materially as a result of known and\nunknown risk factors and uncertainties affecting the Company, including risks\nregarding the medical device industry, regulatory approvals, reimbursement,\neconomic factors, the equity markets generally and risks associated with\ngrowth and competition. Although Profound has attempted to identify important\nfactors that could cause actual actions, events or results to differ\nmaterially from those described in forward-looking statements, there may be\nother factors that cause actions, events or results to differ from those\nanticipated, estimated or intended. No forward-looking statement can be\nguaranteed. Other factors and risks that may cause actual results to differ\nmaterially from those set out in the forward-looking statements are described\nin Profound's Annual Report on Form 10-K and other filings made with U.S. and\nCanadian securities regulators, available at www.sedarplus.com and\nwww.sec.gov. Except as required by applicable securities laws, forward-looking\nstatements speak only as of the date on which they are made and Profound\nundertakes no obligation to publicly update or revise any forward-looking\nstatement, whether as a result of new information, future events, or\notherwise, other than as required by law.\n\nFinancial Outlook\n\nThis press release contains a financial outlook within the meaning of\napplicable securities laws. The financial outlook has been prepared by\nmanagement of the Company to provide an outlook for the Company’s forecasted\nrevenue for the three months ended September 30, 2026, and may not be\nappropriate for any other purpose. The financial outlook has been prepared\nbased on a number of assumptions, including the assumptions discussed under\nthe heading “Forward-Looking Statements” herein. The actual results of the\nCompany’s operations for any period may vary from the amounts set forth in\nthese projections, and such variations may be material. The Company and its\nmanagement believe that the financial outlook has been prepared on a\nreasonable basis. However, because this information is highly subjective and\nsubject to numerous risks, including the risks discussed under the heading\n“Forward-Looking Statements” herein, it should not be relied on as\nnecessarily indicative of future results.\n\nFor further information, please contact:\n\nStephen Kilmer\nInvestor Relations\nskilmer@profoundmedical.com\nT: 647.872.4849\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/94d9e057-9de3-430c-9a19-b41ff3e06a1e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-07T20:15:00.262136582Z","server_sent_at_ms":1791404100262},"received_at":"2026-10-07T20:15:00.437Z","source_url":null},"analysis":{"id":"152037","press_release_id":"163578","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["figures are preliminary and unaudited and may differ from final reported results","no revenue guidance update for Q4 or full year provided"],"eventType":"earnings","narrative":"Profound Medical announced preliminary unaudited Q3 2026 revenue of $9.8-$10.0 million, a record quarter that is 45-47% above the Bloomberg consensus of $6.78 million.\n\nGrowth is up approximately 85-89% year-over-year from $5.3 million and roughly 292-300% sequentially from $2.5 million, with gross margin again expected to exceed 70%.\n\nFull results are due after market close on November 5, 2026, with a 4:30 p.m. ET conference call; figures are preliminary and unaudited.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Small-cap medtech pre-announces a ~45% consensus beat with 3x sequential growth -- watch for gap-up into the Nov 5 full print."},"keyFigures":{"epsBeat":0,"revenue":"$9.8 million to $10.0 million","revenueYoy":"85% to 89%","customDimensions":{"qoq_growth":"292% to 300%","gross_margin":">70%","beat_vs_consensus":"45% to 47%","consensus_revenue":"$6.78 million","prior_year_revenue":"$5.3 million","prior_quarter_revenue":"$2.5 million"}},"quotedText":"The significant increase in revenue we expect to report this quarter represents a historic milestone for Profound, reflecting the strong commercial momentum building behind our technology","namedEntities":{"people":[{"name":"Arun Menawat","role":"CEO and Chairman"},{"name":"Stephen Kilmer","role":"Investor Relations"}],"products":["TULSA-PRO","Sonalleve"],"companies":[{"name":"Profound Medical Corp.","ticker":"PROF","relationship":"filer"},{"name":"Bloomberg","relationship":"consensus data provider"}],"dollarAmounts":[{"amount":"$9.8 million to $10.0 million","context":"preliminary Q3 2026 revenue range"},{"amount":"$5.3 million","context":"Q3 2025 revenue"},{"amount":"$2.5 million","context":"Q2 2026 revenue"},{"amount":"$6.78 million","context":"Bloomberg mean analyst consensus"}]},"materialImpact":{"score":5,"reasoning":"Preliminary Q3 revenue of $9.8-$10.0M is 45-47% above consensus and up ~85-89% YoY with 292-300% sequential growth -- a massive revenue surprise for a small-cap medtech."},"tickerRelevance":{"others":[{"ticker":"PRN","relevance":"TSX listing of same issuer"}],"primary":"PROF"},"globalImportance":42,"audienceRelevance":45,"eventTypeSecondary":["guidance_update"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"large-consensus-beat-preannouncement","sectorWeight":"medtech","surpriseMagnitude":"~46% above consensus"}},"event_type":"earnings","event_type_secondary":["guidance_update"],"sentiment":"bullish","material_impact_score":5,"narrative":"Profound Medical announced preliminary unaudited Q3 2026 revenue of $9.8-$10.0 million, a record quarter that is 45-47% above the Bloomberg consensus of $6.78 million.\n\nGrowth is up approximately 85-89% year-over-year from $5.3 million and roughly 292-300% sequentially from $2.5 million, with gross margin again expected to exceed 70%.\n\nFull results are due after market close on November 5, 2026, with a 4:30 p.m. ET conference call; figures are preliminary and unaudited.","key_figures":{"epsBeat":0,"revenue":"$9.8 million to $10.0 million","revenueYoy":"85% to 89%","customDimensions":{"qoq_growth":"292% to 300%","gross_margin":">70%","beat_vs_consensus":"45% to 47%","consensus_revenue":"$6.78 million","prior_year_revenue":"$5.3 million","prior_quarter_revenue":"$2.5 million"}},"named_entities":{"people":[{"name":"Arun Menawat","role":"CEO and Chairman"},{"name":"Stephen Kilmer","role":"Investor Relations"}],"products":["TULSA-PRO","Sonalleve"],"companies":[{"name":"Profound Medical Corp.","ticker":"PROF","relationship":"filer"},{"name":"Bloomberg","relationship":"consensus data provider"}],"dollarAmounts":[{"amount":"$9.8 million to $10.0 million","context":"preliminary Q3 2026 revenue range"},{"amount":"$5.3 million","context":"Q3 2025 revenue"},{"amount":"$2.5 million","context":"Q2 2026 revenue"},{"amount":"$6.78 million","context":"Bloomberg mean analyst consensus"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-07T20:15:06.419Z","global_importance":42,"audience_relevance":45,"importance_components":{"tickerTier":"small-cap","eventGravity":"large-consensus-beat-preannouncement","sectorWeight":"medtech","surpriseMagnitude":"~46% above consensus"}},"durationMs":5960,"modelName":"glm-5.3-flashx"}}